-
Something wrong with this record ?
Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence
A. Zanchetti, L. Liu, G. Mancia, G. Parati, G. Grassi, M. Stramba-Badiale, V. Silani, G. Bilo, G. Corrao, A. Zambon, L. Scotti, X. Zhang, H. Wang, Y. Zhang, X. Zhang, TR. Guan, E. Berge, J. Redon, K. Narkiewicz, A. Dominiczak, P. Nilsson, M....
Language English Country England, Great Britain
Document type Journal Article, Review
- MeSH
- Stroke prevention & control MeSH
- Cholesterol MeSH
- Hypercholesterolemia drug therapy MeSH
- Cognition MeSH
- Cognition Disorders prevention & control MeSH
- Blood Pressure drug effects MeSH
- Cholesterol, LDL blood MeSH
- Humans MeSH
- Primary Prevention MeSH
- Randomized Controlled Trials as Topic MeSH
- Recurrence MeSH
- Secondary Prevention MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
BACKGROUND AND OBJECTIVES: It is well established by a large number of randomized controlled trials that lowering blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) by drugs are powerful means to reduce stroke incidence, but the optimal BP and LDL-C levels to be achieved are largely uncertain. Concerning BP targets, two hypotheses are being confronted: first, the lower the BP, the better the treatment outcome, and second, the hypothesis that too low BP values are accompanied by a lower benefit and even higher risk. It is also unknown whether BP lowering and LDL-C lowering have additive beneficial effects for the primary and secondary prevention of stroke, and whether these treatments can prevent cognitive decline after stroke. RESULTS: A review of existing data from randomized controlled trials confirms that solid evidence on optimal BP and LDL-C targets is missing, possible interactions between BP and LDL-C lowering treatments have never been directly investigated, and evidence in favour of a beneficial effect of BP or LDL-C lowering on cognitive decline is, at best, very weak. CONCLUSION: A new, large randomized controlled trial is needed to determine the optimal level of BP and LDL-C for the prevention of recurrent stroke and cognitive decline.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000713
- 003
- CZ-PrNML
- 005
- 20160126095904.0
- 007
- ta
- 008
- 160108s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/HJH.0000000000000253 $2 doi
- 035 __
- $a (PubMed)24979302
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Zanchetti, Alberto $u aIstituto Auxologico Italiano bUniversità di Milano, Milan, Italy cFuWai Hospital and Cardiovascular Institute dBeijing Hypertension League Institute, Beijing, China eUniversità Milano-Bicocca fIRCCS Multimedica, Sesto San Giovanni, Milan, Italy gOslo University Hospital, Oslo, Norway hUniversity of Valencia, Madrid, Spain iMedical University of Gdansk, Gdansk, Poland jUniversity of Glasgow, Glasgow, UK kLund University, Scania University Hospital, Malmo, Sweden lTallinn University of Technology, Tallinn, Estonia mEuropean Hospital Georges Pompidou, Paris, France nUniversità di Brescia, Spedali Civili, Brescia, Italy oBeijing Anzhen Hospital, Beijing pShanghai Hypertension Institute, Shanghai, China qComplutense University rHospital 12 de Octubre sHospital Clínico San Carlos, Madrid, Spain tCentro Hospitalar de Entre o Douro e Vouga, E.P.E., Portugal uNephrology and Hypertension, University Hospital, Erlangen, Germany vUniversity Hospital of Lausanne, Lausanne, Switzerland wMedical University of Lodz, Lodz, Poland xCharles University Medical School I and Thomayer Hospital, Prague, Czech Republic ySt. Imre University Teaching Hospital, Budapest, Hungary zAlmazov Federal Heart, Blood and Endocrinology Center, St. Petersburg, Russia aaRSPC Cardiology, Minsk, Belarus abNSC 'Institute of Cardiology named after N.D. Strazhesko' of NAMS, Kiev, Ukraine acEmergency Hospital of Bucharest, Bucharest, Romania adUniversity Hospital Saint Anna, Sofia, Bulgaria aeDr Peter Drzai Hospital, Ljubljana, Slovenia afUniversity Hospital Center Zagreb, Zagreb, Croatia agClinic for Internal Medicine InterMedic, Nis, Serbia ahCardiology Department, Asklepeion General Hospital, Athens, Greece aiNicosia General Hospital, Nicosia, Cyprus ajIstanbul University Cerrahpaşa School of Medicine, Istanbul, Turkey akHasharon Hospital - Rabin Medical Center, Petach-Tikva, Israel alBeijing Xuanwu Hospital amSecond Affiliate Hospital, Beijing University anMilitary General Hospital, Beijing, China aoH
- 245 10
- $a Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence / $c A. Zanchetti, L. Liu, G. Mancia, G. Parati, G. Grassi, M. Stramba-Badiale, V. Silani, G. Bilo, G. Corrao, A. Zambon, L. Scotti, X. Zhang, H. Wang, Y. Zhang, X. Zhang, TR. Guan, E. Berge, J. Redon, K. Narkiewicz, A. Dominiczak, P. Nilsson, M. Viigimaa, S. Laurent, E. Agabiti-Rosei, Z. Wu, D. Zhu, JL. Rodicio, LM. Ruilope, N. Martell-Claros, F. Pinto, RE. Schmieder, M. Burnier, M. Banach, R. Cifkova, C. Farsang, A. Konradi, I. Lazareva, Y. Sirenko, M. Dorobantu, A. Postadzhiyan, R. Accetto, B. Jelakovic, D. Lovic, AJ. Manolis, P. Stylianou, S. Erdine, D. Dicker, G. Wei, C. Xu, H. Xie, A. Coca, J. O'Brien, G. Ford,
- 520 9_
- $a BACKGROUND AND OBJECTIVES: It is well established by a large number of randomized controlled trials that lowering blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) by drugs are powerful means to reduce stroke incidence, but the optimal BP and LDL-C levels to be achieved are largely uncertain. Concerning BP targets, two hypotheses are being confronted: first, the lower the BP, the better the treatment outcome, and second, the hypothesis that too low BP values are accompanied by a lower benefit and even higher risk. It is also unknown whether BP lowering and LDL-C lowering have additive beneficial effects for the primary and secondary prevention of stroke, and whether these treatments can prevent cognitive decline after stroke. RESULTS: A review of existing data from randomized controlled trials confirms that solid evidence on optimal BP and LDL-C targets is missing, possible interactions between BP and LDL-C lowering treatments have never been directly investigated, and evidence in favour of a beneficial effect of BP or LDL-C lowering on cognitive decline is, at best, very weak. CONCLUSION: A new, large randomized controlled trial is needed to determine the optimal level of BP and LDL-C for the prevention of recurrent stroke and cognitive decline.
- 650 _2
- $a krevní tlak $x účinky léků $7 D001794
- 650 _2
- $a cholesterol $7 D002784
- 650 _2
- $a LDL-cholesterol $x krev $7 D008078
- 650 _2
- $a kognice $7 D003071
- 650 _2
- $a kognitivní poruchy $x prevence a kontrola $7 D003072
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypercholesterolemie $x farmakoterapie $7 D006937
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a primární prevence $7 D011322
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 650 _2
- $a recidiva $7 D012008
- 650 _2
- $a sekundární prevence $7 D055502
- 650 _2
- $a cévní mozková příhoda $x prevence a kontrola $7 D020521
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Liu, Lisheng
- 700 1_
- $a Mancia, Giuseppe
- 700 1_
- $a Parati, Gianfranco
- 700 1_
- $a Grassi, Guido
- 700 1_
- $a Stramba-Badiale, Marco
- 700 1_
- $a Silani, Vincenzo
- 700 1_
- $a Bilo, Grzegorz
- 700 1_
- $a Corrao, Giovanni
- 700 1_
- $a Zambon, Antonella
- 700 1_
- $a Scotti, Lorenza
- 700 1_
- $a Zhang, Xinhua
- 700 1_
- $a Wang, HayYan
- 700 1_
- $a Zhang, Yuqing
- 700 1_
- $a Zhang, Xuezhong
- 700 1_
- $a Guan, Ting Rui
- 700 1_
- $a Berge, Eivind
- 700 1_
- $a Redon, Josep
- 700 1_
- $a Narkiewicz, Krzysztof
- 700 1_
- $a Dominiczak, Anna
- 700 1_
- $a Nilsson, Peter
- 700 1_
- $a Viigimaa, Margus
- 700 1_
- $a Laurent, Stéphane
- 700 1_
- $a Agabiti-Rosei, Enrico $7 gn_A_00002053
- 700 1_
- $a Wu, Zhaosu
- 700 1_
- $a Zhu, Dingliang
- 700 1_
- $a Rodicio, José Luis
- 700 1_
- $a Ruilope, Luis Miguel
- 700 1_
- $a Martell-Claros, Nieves
- 700 1_
- $a Pinto, Fernando
- 700 1_
- $a Schmieder, Roland E
- 700 1_
- $a Burnier, Michel
- 700 1_
- $a Banach, Maciej
- 700 1_
- $a Cifkova, Renata
- 700 1_
- $a Farsang, Csaba
- 700 1_
- $a Konradi, Alexandra
- 700 1_
- $a Lazareva, Irina
- 700 1_
- $a Sirenko, Yuriy
- 700 1_
- $a Dorobantu, Maria
- 700 1_
- $a Postadzhiyan, Arman
- 700 1_
- $a Accetto, Rok $7 gn_A_00000954
- 700 1_
- $a Jelakovic, Bojan
- 700 1_
- $a Lovic, Dragan
- 700 1_
- $a Manolis, Athanasios J
- 700 1_
- $a Stylianou, Philippos
- 700 1_
- $a Erdine, Serap
- 700 1_
- $a Dicker, Dror
- 700 1_
- $a Wei, Gangzhi
- 700 1_
- $a Xu, Chengbin
- 700 1_
- $a Xie, Hengge
- 700 1_
- $a Coca, Antonio
- 700 1_
- $a O'Brien, John
- 700 1_
- $a Ford, Gary
- 773 0_
- $w MED00002723 $t Journal of hypertension $x 1473-5598 $g Roč. 32, č. 9 (2014), s. 1741-50
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24979302 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20160126100027 $b ABA008
- 999 __
- $a ok $b bmc $g 1102994 $s 924919
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 32 $c 9 $d 1741-50 $i 1473-5598 $m Journal of hypertension $n J Hypertens $x MED00002723
- LZP __
- $a Pubmed-20160108